[Skip to Content]
[Skip to Content Landing]
Views 845
Citations 0
Review
March 12, 2018

The Changing Landscape of Pediatric Migraine TherapyA Review

Author Affiliations
  • 1Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
  • 2Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia
JAMA Neurol. Published online March 12, 2018. doi:10.1001/jamaneurol.2018.0046
Abstract

Importance  Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population. This review describes current acute and preventive migraine pharmacologic therapies for the pediatric and adolescent population.

Observations  Multiple pharmacotherapies that have been used in the treatment of acute headache and prevention in pediatric migraine are reviewed. There have been recent advances in the management of migraines among pediatric and adolescent patients, including US Food and Drug Administration approval of triptans for acute management in children as young as 6 years, and the first prospective, randomized, double-blind, placebo-controlled comparative study of preventive pharmacotherapy in pediatric migraine. A major challenge of evidence-based research in pediatric and adolescent migraine is the significant placebo effect.

Conclusions and Relevance  Although progress is being made in the management of migraines among pediatric and adolescent patients, there remains much work to be done.

×